3-(bromomethyl)-N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]benzamide | 849622-95-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(bromomethyl)-N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]benzamide
• CAS: 849622-95-3
• 化学式: C₁₈H₂₀BrFN₂O₃S
• 分子量: 443.337
• InChiKey: CKNXNVIEPHCBSU-GFCCVEGCSA-N

物化性质

• 密度：
  1.475±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(bromomethyl)-N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]benzamide 在 盐酸 、 caesium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 3-({[(1r)-1-(4-Fluorophenyl)ethyl]amino}carbonyl)-5-[methyl(Methylsulfonyl)amino]benzyl Alpha-Methyl-D-Phenylalaninate
  参考文献：
  名称：

  发现了β-分泌酶（BACE-1）的恶二唑基叔卡宾胺抑制剂。

  摘要：

  我们描述了酶β-分泌酶（BACE-1）的叔卡宾胺衍生抑制剂的发现和优化。这些新的非过渡态衍生的配体结合了一个伯胺与目标酶的催化天冬氨酸相互作用。该系列的优化为抑制剂提供了与进化的过渡态等位基因衍生的BACE-1抑制剂相当的内在和功能性抑制剂。

  DOI：

  10.1021/jm061046r
• 作为产物：
  描述：

  (R)-1-(4-氟苯基)乙胺 在 lithium hydroxide 、 N-羟基-7-氮杂苯并三氮唑 、 四溴化碳 、 硼烷 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 氯仿 、 乙腈 为溶剂， 反应 59.08h， 生成 3-(bromomethyl)-N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]benzamide
  参考文献：
  名称：

  发现了β-分泌酶（BACE-1）的恶二唑基叔卡宾胺抑制剂。

  摘要：

  我们描述了酶β-分泌酶（BACE-1）的叔卡宾胺衍生抑制剂的发现和优化。这些新的非过渡态衍生的配体结合了一个伯胺与目标酶的催化天冬氨酸相互作用。该系列的优化为抑制剂提供了与进化的过渡态等位基因衍生的BACE-1抑制剂相当的内在和功能性抑制剂。

  DOI：

  10.1021/jm061046r

文献信息

• [EN] BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE BENZYLETHER ET BENZYLAMINO DE BETA-SECRETASE POUR TRAITER LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2005051914A1

  公开（公告）日：2005-06-09

  The present invention is directed to benzylether and benzylamino derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及苯乙醚和苄胺衍生物化合物，这些化合物是β-分泌酶的抑制剂，并且在治疗涉及β-分泌酶的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗涉及β-分泌酶的这类疾病中使用这些化合物和组合物。
• Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
  申请人：Nantermet G. Philippe

  公开号：US20070088165A1

  公开（公告）日：2007-04-19

  The present invention is directed to benzylether and benzylamino derivative compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的苯甲醚和苯甲氨基衍生物化合物，它们是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶涉及的疾病，例如阿尔茨海默病中有用。本发明还涉及包含这些化合物的制药组合物以及在治疗β-分泌酶酶涉及的疾病中使用这些化合物和组合物的用途。
• Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease
  申请人：Merck & Co., Inc.

  公开号：US07354942B2

  公开（公告）日：2008-04-08

  The present invention is directed to benzylether and benzylamino derivative compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式（I）的苄醚和苄氨基衍生物化合物，它们是β-分泌酶酶的抑制剂，可用于治疗β-分泌酶酶参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物治疗β-分泌酶酶参与的疾病的方法。
• BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Nantermet Philippe G.

  公开号：US20100210693A1

  公开（公告）日：2010-08-19

  The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及一类抑制β-分泌酶酶的化合物，这些化合物在治疗β-分泌酶酶参与的疾病，例如阿尔茨海默病中有用。本发明还涉及包含这些化合物的药物组合物，以及在治疗β-分泌酶酶参与的这些疾病中使用这些化合物和组合物的用途。
• [EN] BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE TYPE BENZYLETHER ET BENZYLAMINO DE BETA-SECRETASE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2005032471A3

  公开（公告）日：2005-07-07